Adicet Bio, Inc. (0HX7.L)
USD 0.92
(-3.81%)
USD 0.92
(-3.81%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -93.71 Thousand | -45.12 Million | -51.31 Million | -41.7 Million | -27.88 Million | -36.42 Million |
| Net Income | -142.65 Thousand | -69.79 Million | -61.99 Million | -36.67 Million | -28.13 Million | -37.61 Million |
| Depreciation & Amortization | 6128.00 | 5 Million | 4.06 Million | 1.95 Million | 1.23 Million | 80 Thousand |
| Deferred income taxes | -34.13 Million | -17.31 Million | -12.48 Million | -9.97 Million | -3.12 Million | - |
| Stock-based compensation | 20.25 Thousand | 17.12 Million | 12.51 Million | 5.26 Million | 1.17 Million | 2.47 Million |
| Change in working capital | 1935.00 | 2.74 Million | -6.05 Million | -13.52 Million | 341 Thousand | -36 Thousand |
| Other non-cash items | 20.61 Thousand | 25.03 Million | 19.7 Million | 11.25 Million | 626 Thousand | -287 Thousand |
| Investing Cash Flow | -4464.00 | -16.78 Million | -2.79 Million | 115.21 Million | -47.93 Million | -100.71 Million |
| Investments in PPE | -4464.00 | -16.78 Million | -13.04 Million | -990 Thousand | -1.07 Million | -362 Thousand |
| Acquisitions | - | - | - | 64.11 Million | 118 Thousand | - |
| Investment purchases | - | - | - | -5.7 Million | -76.07 Million | -107.85 Million |
| Sales/Maturities of investments | - | - | 10.25 Million | 57.79 Million | 29.09 Million | 7.5 Million |
| Other Investing Activities | - | - | 10.25 Million | 64.11 Million | -46.86 Million | -15.18 Million |
| Financing Cash Flow | 236.00 | 41.87 Million | 242.94 Million | 460 Thousand | 76.94 Million | 90.82 Million |
| Debt repayment | - | - | - | - | - | -84 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -150.00 | -3.23 Million | - | - | - | - |
| Common Stock Issuance | 386 Thousand | 45.1 Million | 242.94 Million | 460 Thousand | 76.94 Million | 90.91 Million |
| Other Financing Activities | 386.00 | -3.23 Million | 242.68 Million | 303 Thousand | 76.94 Million | 11.04 Million |
| Accounts receivables | - | 185 Thousand | -30 Thousand | - | - | - |
| Accounts payables | -1.68 Million | 1.71 Million | 1.13 Million | -814 Thousand | 527 Thousand | 1.59 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1935.00 | 849 Thousand | -7.16 Million | -12.71 Million | -186 Thousand | -1.63 Million |
| Cash at beginning of period | 257.65 Thousand | 277.54 Million | 84.33 Million | 10.6 Million | 7.04 Million | 53.34 Million |
| Cash at end of period | 159.71 Thousand | 257.65 Million | 277.54 Million | 84.33 Million | 10.6 Million | 7.04 Million |
| Capital Expenditure | -4464.00 | -16.78 Million | -13.04 Million | -990 Thousand | -1.07 Million | -362 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | 36.94 Million |
| Net cash flow / Change in cash | -97.94 Thousand | -19.88 Million | 193.21 Million | 73.72 Million | 3.56 Million | -46.3 Million |
| Free Cash Flow | -98.18 Thousand | -61.91 Million | -64.35 Million | -42.69 Million | -28.95 Million | -36.78 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -29.9 Million | -28.01 Million | -142.65 Million | -29.48 Million | -49.88 Million | -32.4 Million |
| Depreciation & Amortization | 1.6 Million | 1.65 Million | 6.09 Million | 1.68 Million | 2.34 Million | 2.28 Million |
| Deferred income taxes | - | - | -34.13 Million | -9.74 Million | -8.85 Million | -8.88 Million |
| Stock-based compensation | 6 Million | 5.67 Million | 20.25 Million | 4.91 Million | 5.56 Million | 5.02 Million |
| Change in working capital | -1.35 Million | -2.97 Million | 252 Thousand | -1.35 Million | 1.23 Million | 186 Thousand |
| Other non-cash items | 226 Thousand | 10 Million | 56.47 Million | 10.5 Million | 28.36 Million | 8.89 Million |
| Investing Cash Flow | -302 Thousand | -239 Thousand | -4.46 Million | -136 Thousand | -906 Thousand | -1.5 Million |
| Investments in PPE | -302 Thousand | -239 Thousand | -4.46 Million | -136 Thousand | -906 Thousand | -1.5 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 204 Thousand | 110.96 Million | 236 Thousand | 76 Thousand | -59 Thousand | 226 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -141 Thousand | -150 Thousand | -81 Thousand | -59 Thousand | - |
| Common Stock Issuance | 204 Thousand | 111.1 Million | 386 Thousand | 157 Thousand | - | 226 Thousand |
| Other Financing Activities | 204 Thousand | -141 Thousand | -150 Thousand | -81 Thousand | -59 Thousand | 226 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -567 Thousand | -208 Thousand | -1.68 Million | -1.46 Million | 1.4 Million | 709 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -1.35 Million | -2.77 Million | 1.93 Million | 105 Thousand | -170 Thousand | -523 Thousand |
| Cash at beginning of period | 247.58 Million | 159.71 Million | 257.65 Million | 183.25 Million | 205.46 Million | 231.64 Million |
| Cash at end of period | 224.06 Million | 247.58 Million | 159.71 Million | 159.71 Million | 183.25 Million | 205.46 Million |
| Capital Expenditure | -302 Thousand | -239 Thousand | -4.46 Million | -136 Thousand | -906 Thousand | -1.5 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -23.52 Million | 87.87 Million | -97.94 Million | -23.54 Million | -22.2 Million | -26.18 Million |
| Free Cash Flow | -23.72 Million | -23.08 Million | -98.18 Million | -23.62 Million | -22.14 Million | -26.4 Million |
HCLTECH
2880
603041
ISEC
MAVEN
T9Z